Pierre Vandepapelière

3.0k total citations · 1 hit paper
35 papers, 2.3k citations indexed

About

Pierre Vandepapelière is a scholar working on Epidemiology, Immunology and Hepatology. According to data from OpenAlex, Pierre Vandepapelière has authored 35 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 14 papers in Immunology and 6 papers in Hepatology. Recurrent topics in Pierre Vandepapelière's work include Hepatitis B Virus Studies (16 papers), Hepatitis Viruses Studies and Epidemiology (6 papers) and Immunotherapy and Immune Responses (6 papers). Pierre Vandepapelière is often cited by papers focused on Hepatitis B Virus Studies (16 papers), Hepatitis Viruses Studies and Epidemiology (6 papers) and Immunotherapy and Immune Responses (6 papers). Pierre Vandepapelière collaborates with scholars based in Belgium, Switzerland and France. Pierre Vandepapelière's co-authors include Geert Leroux‐Roels, M. Slaoui, Lawrence R. Stanberry, Gary Dubin, Martine Wettendorff, Spotswood L. Spruance, Martine Denis, Stephen K. Tyring, David I. Bernstein and Anthony L. Cunningham and has published in prestigious journals such as New England Journal of Medicine, ACS Nano and Gastroenterology.

In The Last Decade

Pierre Vandepapelière

35 papers receiving 2.2k citations

Hit Papers

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
    2002 583 citations Lawrence R. Stanberry, Spotswood L. Spruance et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre Vandepapelière Belgium 23 1.4k 923 415 349 298 35 2.3k
Margaret Chen Sweden 28 1.6k 1.1× 1.5k 1.6× 1.3k 3.1× 549 1.6× 861 2.9× 96 4.0k
Isabelle Desombere Belgium 29 1.6k 1.1× 569 0.6× 1.4k 3.4× 514 1.5× 265 0.9× 72 2.4k
Thomas C. Heineman United States 31 3.2k 2.3× 698 0.8× 153 0.4× 586 1.7× 285 1.0× 71 3.9k
J Pillot France 29 1.2k 0.8× 697 0.8× 976 2.4× 738 2.1× 369 1.2× 129 2.6k
M Just Switzerland 24 1.0k 0.7× 349 0.4× 197 0.5× 356 1.0× 213 0.7× 86 1.7k
Giulietta Saletti Germany 17 514 0.4× 502 0.5× 334 0.8× 394 1.1× 237 0.8× 30 1.4k
J. Wai‐Kuo Shih United States 28 1.6k 1.1× 337 0.4× 1.2k 2.9× 706 2.0× 327 1.1× 46 2.7k
Linda L. Yasukawa United States 26 1.4k 1.0× 493 0.5× 130 0.3× 910 2.6× 126 0.4× 38 2.1k
Alexandra Valsamakis United States 31 1.9k 1.3× 380 0.4× 351 0.8× 883 2.5× 435 1.5× 71 2.8k
Christopher J. Burrell Australia 30 972 0.7× 418 0.5× 434 1.0× 645 1.8× 388 1.3× 80 2.2k

Countries citing papers authored by Pierre Vandepapelière

Since Specialization
Citations

This map shows the geographic impact of Pierre Vandepapelière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Vandepapelière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Vandepapelière more than expected).

Fields of papers citing papers by Pierre Vandepapelière

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Vandepapelière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Vandepapelière. The network helps show where Pierre Vandepapelière may publish in the future.

Co-authorship network of co-authors of Pierre Vandepapelière

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Vandepapelière. A scholar is included among the top collaborators of Pierre Vandepapelière based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Vandepapelière. Pierre Vandepapelière is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rampelbergh, Jean Van, Peter Achenbach, Richard David Leslie, et al.. (2023). First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes. BMC Medicine. 21(1). 190–190. 13 indexed citations
2.
Lam, Jian Hang, et al.. (2022). Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. ACS Nano. 16(10). 16757–16775. 23 indexed citations
3.
4.
Durez, Patrick, Pierre Vandepapelière, Pedro C. Miranda, et al.. (2014). Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS ONE. 9(12). e113465–e113465. 35 indexed citations
5.
Leroux‐Roels, Isabel, Jeanne‐Marie Devaster, Geert Leroux‐Roels, et al.. (2013). Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials. Vaccine. 33(4). 577–584. 52 indexed citations
6.
Leroux‐Roels, Isabel, Geert Leroux‐Roels, Frédéric Clément, et al.. (2012). A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults. The Journal of Infectious Diseases. 206(8). 1280–1290. 112 indexed citations
7.
Lauwerys, Bernard, É. Hachulla, François Spertini, et al.. (2012). Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid. Arthritis & Rheumatism. 65(2). 447–456. 132 indexed citations
8.
Spertini, François, R Audran, Opokua Ofori‐Anyinam, et al.. (2012). The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study. Tuberculosis. 93(2). 179–188. 42 indexed citations
9.
Mathian, Alexis, Zahir Amoura, Estelle Adam, et al.. (2011). Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 70(6). 1138–1143. 40 indexed citations
10.
Vandepapelière, Pierre, Yves Horsmans, Philippe Moris, et al.. (2008). Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine. 26(10). 1375–1386. 168 indexed citations
11.
12.
Goepfert, Paul A., Georgia D. Tomaras, Helen Horton, et al.. (2006). Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine. 25(3). 510–518. 71 indexed citations
13.
Bienzle, Ulrich, Matthias Günther, R. Neuhaus, et al.. (2003). Immunization With An Adjuvant Hepatitis B Vaccine After Liver Transplantation for Hepatitis B–Related Disease. Hepatology. 38(4). 811–819. 108 indexed citations
14.
Stanberry, Lawrence R., Spotswood L. Spruance, Anthony L. Cunningham, et al.. (2002). Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes. New England Journal of Medicine. 347(21). 1652–1661. 583 indexed citations breakdown →
15.
Vandepapelière, Pierre. (2002). Therapeutic vaccination against chronic viral infections. The Lancet Infectious Diseases. 2(6). 353–367. 24 indexed citations
16.
17.
Leroux‐Roels, Geert, et al.. (1993). Immunogenicity of a new hepatitis B vaccine containing preS1 and preS2 epitopes. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
18.
Degaute, J.P., et al.. (1992). Acute and chronic effects of lisinopril on renal and systemic hemodynamics in hypertension. Cardiovascular Drugs and Therapy. 6(5). 489–494. 4 indexed citations
19.
Damme, Pierre Van, et al.. (1992). Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine. 10(6). 366–367. 37 indexed citations
20.
Vandepapelière, Pierre, et al.. (1989). Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension.. PubMed. 3 Suppl 1. 163–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaret Chen Breakdown of academic impact, for papers by Isabelle Desombere Breakdown of academic impact, for papers by Thomas C. Heineman Breakdown of academic impact, for papers by J Pillot Breakdown of academic impact, for papers by M Just Breakdown of academic impact, for papers by Giulietta Saletti Breakdown of academic impact, for papers by J. Wai‐Kuo Shih Breakdown of academic impact, for papers by Linda L. Yasukawa Breakdown of academic impact, for papers by Alexandra Valsamakis Breakdown of academic impact, for papers by Christopher J. Burrell
Rankless by CCL
2026